Actavis, Ironwood mount second DTC push for GI med Linzess

With Actavis ($ACT) and Ironwood's ($IRWD) first DTC campaign for GI med Linzess, the goal was to help patients identify irritable bowel syndrome with constipation and chronic idiopathic constipation by clearly communicating the symptoms. Now that the team is back with its sophomore DTC effort, the goal is to encourage patients to find a solution to their problems. A branded, prescription solution. More from FiercePharmaMarketing